Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Subscribe To Our Newsletter & Stay Updated
